Search

Your search keyword '"Vakar-Lopez, Funda"' showing total 16 results
Start Over Author "Vakar-Lopez, Funda" Journal journal of urology
16 results on '"Vakar-Lopez, Funda"'

1. MP35-18 AGREEMENT BETWEEN TRANSURETHRAL RESECTION OF BLADDER TUMOR (TURBT) AND RADICAL CYSTECTOMY (RC) PATHOLOGY IN PATIENTS WITH BLADDER CANCER SUBTYPE HISTOLOGY

Author

Bakaloudi, Dimitra Rafailia, primary, Koehne, Elizabeth L., additional, Makrakis, Dimitrios, additional, Diamandopoulos, Leonidas N., additional, Grivas, Petros, additional, Winters, Brian R., additional, True, Lawrence D., additional, Tretiakova, Maria S., additional, Psutka, Sarah P., additional, Holt, Sarah K., additional, John, Gore L., additional, Lin, Daniel W., additional, Schade, George R., additional, Nyame, Yaw, additional, Hsieh, Andrew C., additional, Lee, John K., additional, Yezefski, Todd, additional, Hawley, Jessica, additional, Schweizer, Michael T., additional, Cheng, Heather H., additional, Yu, Evan Y., additional, Vakar-Lopez, Funda, additional, Montgomery, Bruce R., additional, and Wright, Jonathan, additional

Published
2024
Full Text
View/download PDF

2. PD10-06 A PHASE 1/2 STUDY OF RAPAMYCIN AND CISPLATIN/GEMCITABINE FOR TREATMENT OF PATIENTS (PTS) WITH MUSCLE-INVASIVE BLADDER CANCER (NCT01938573)

Author

Makrakis, Dimitrios, primary, Roudier, Martine, additional, Wang, Yan, additional, Vakar-Lopez, Funda, additional, Garcia, Jose, additional, Dash, Atreya, additional, Lin, Daniel, additional, Schade, George, additional, Mostaghel, Elahe A., additional, Cheng, Heather, additional, Schweizer, Michael T., additional, Holt, Sarah K., additional, Gore, John L., additional, Yu, Evan, additional, Lam, Hung-Ming, additional, Wright, Jonathan L., additional, and Montgomery, Bruce, additional

Published
2022
Full Text
View/download PDF

3. PD53-09 ANTIBODY DRUG CONJUGATES AND VARIANT HISTOLOGY MUSCLE-INVASIVE BLADDER CANCER: ARE THE TARGETS PRESENT IN PRIMARY AND/OR METASTATIC TUMORS?

Author

Ghali, Fady, primary, Roudier, Martine, additional, Vakar-Lopez, Funda, additional, Garcia, Jose, additional, Wang, Yan, additional, Ha, Gavin, additional, Grivas, Petros, additional, Lee, John, additional, Yu, Evan, additional, Montgomery, Bruce, additional, Hsieh, Andrew, additional, Wright, Jonathan, additional, and Lam, Hung-Ming, additional

Published
2022
Full Text
View/download PDF

4. MP06-05 UROTHELIAL CANCER RAPID AUTOPSY PROGRAM: BIOSPECIMENS AND PATIENT-DERIVED PRECLINICAL MODELS

Author

Garcia, Jose, primary, Vakar-Lopez, Funda, additional, Roudier, Martine, additional, Grivas, Petros, additional, Yu, Evan Y., additional, Cheng, Heather, additional, Schweizer, Michael T., additional, Haffner, Michael, additional, Lee, John K., additional, Corey, Eva, additional, Montgomery, Bruce, additional, Hsieh, Andrew, additional, Wright, Jonathan L., additional, and Lam, Hung-Ming, additional

Published
2022
Full Text
View/download PDF

5. PD62-06 DISTINCT GENOMIC HALLMARKS EXIST BETWEEN METASTATIC UPPER AND LOWER TRACT UROTHELIAL CARCINOMA

Author

Winters*, Brian, primary, De Sarkar, Navonil, additional, Arora, Sonali, additional, Bolouri, Hamid, additional, Vakar-Lopez, Funda, additional, Cheng, Heather, additional, Schweizer, Michael, additional, Yu, Evan, additional, Kollath, Lori, additional, Grivas, Petros, additional, McFerrin, Lisa, additional, Montgomery, Bruce, additional, Wright, Jonathan, additional, Lam, Hung-Ming, additional, and Hsieh, Andrew, additional

Published
2019
Full Text
View/download PDF

10. 959 IMMUNOHISTOCHEMICAL EXPRESSION OF ERG ONCOPROTEIN IS ASSOCIATED WITH DEVELOPMENT OF LOCAL RECURRENCE AND PROSTATE CANCER-SPECIFIC DEATH IN MEN TREATED WITH RADICAL PROSTATECTOMY

Author

Spencer, Elysia Sophia, primary, Johnston, Richard, additional, Lewinshtein, Dan, additional, Gordon, Ryan R., additional, Koo, Sandra, additional, Dobi, Albert, additional, McLeod, David G., additional, Vakar-Lopez, Funda, additional, Srivastava, Shiv, additional, Gleave, Martin, additional, Nelson, Peter, additional, and Porter, Christopher, additional

Published
2012
Full Text
View/download PDF

11. 2112 CORRELATION OF URINE PCA3 SCORE AND TMPRS2:ERG SCORE WITH CLINICALLY SIGNIFICANT TUMOR VOLUME IN RADICAL PROSTATECTOMY SPECIMENS: INTERIM RESULTS FROM A MULTI-CENTER PROSPECTIVE STUDY

Author

Davis, John, primary, Troncoso, Patricia, additional, Meyer, Sarah, additional, Day, John, additional, Groskopf, Jack, additional, Aubin, Sheila, additional, Rodriguez, Yvonne, additional, Lin, Dan W., additional, Vakar-Lopez, Funda, additional, Magi-Galluzzi, Cristina, additional, and Berglund, Ryan, additional

Published
2012
Full Text
View/download PDF

15. The Potential Impact of Reproducibility of Gleason Grading in Men With Early Stage Prostate Cancer Managed by Active Surveillance: A Multi-Institutional Study.

Author

McKenney, Jesse K., Simko, Jeff, Bonham, Michael, True, Lawrence D., Troyer, Dean, Hawley, Sarah, Newcomb, Lisa F., Fazli, Ladan, Kunju, Lakshmi P., Nicolas, Marlo M., Vakar-Lopez, Funda, Zhang, Xiaotun, Carroll, Peter R., and Brooks, James D.

Subjects
PROSTATE cancer treatment, CANCER prognosis, PUBLIC health surveillance, ADENOCARCINOMA, PROSTATE-specific antigen, BIOPSY, PATHOLOGISTS, HISTOLOGY
Abstract

Purpose: We evaluated the reproducibility of Gleason grading as relevant to the clinical treatment of men on active surveillance. Materials and Methods: Three sets of digital images of prostatic adenocarcinoma in biopsies were reviewed and assigned Gleason scores by a total of 11 pathologists from 7 institutions. Interobserver and intra-observer reproducibility were assessed for assignment of the highest Gleason pattern (3 vs 4 or higher). We also identified 97 consecutive patients on active surveillance. Prostate biopsy glass slides from 82 of the patients were available for re-review and the frequency of carcinoma requiring the distinction of tangentially sectioned Gleason pattern 3 from 4 was determined. Results: Interobserver reproducibility for classic Gleason patterns was substantial (Light''s κ 0.76). Interobserver reproducibility for the histological distinction of tangentially sectioned Gleason pattern 3 from Gleason pattern 4 was only fair (Light''s κ 0.27). Intra-observer reproducibility ranged from 65% to 100% (mean 81.5%). Of the 82 patients on active surveillance 61 had carcinoma and 15 (24.5%) had a set of biopsies with at least 1 focus in which the distinction between tangentially sectioned Gleason pattern 3 and poorly formed pattern 4 glands had to be considered. Conclusions: The reproducibility of grading classic Gleason patterns is high. However, variability in grading occurred when distinguishing between tangentially sectioned pattern 3 glands and the poorly formed gland subset of pattern 4. Developing universally accepted histological and/or molecular criteria to distinguish these patterns and subsequently characterizing their natural history would be useful when treating patients on active surveillance. [Copyright &y& Elsevier]

Published
2011
Full Text
View/download PDF

16. Outcomes of Active Surveillance for Clinically Localized Prostate Cancer in the Prospective, Multi-Institutional Canary PASS Cohort.

Author

Newcomb LF, Thompson IM Jr, Boyer HD, Brooks JD, Carroll PR, Cooperberg MR, Dash A, Ellis WJ, Fazli L, Feng Z, Gleave ME, Kunju P, Lance RS, McKenney JK, Meng MV, Nicolas MM, Sanda MG, Simko J, So A, Tretiakova MS, Troyer DA, True LD, Vakar-Lopez F, Virgin J, Wagner AA, Wei JT, Zheng Y, Nelson PS, and Lin DW

Subjects
Aged, Biomarkers, Tumor analysis, Biopsy, Humans, Male, Middle Aged, Neoplasm Grading, Population Surveillance, Prospective Studies, Prostatectomy, Prostatic Neoplasms surgery, Risk Factors, Treatment Outcome, Tumor Burden, Prostatic Neoplasms pathology, Watchful Waiting
Abstract

Purpose: Active surveillance represents a strategy to address the overtreatment of prostate cancer, yet uncertainty regarding individual patient outcomes remains a concern. We evaluated outcomes in a prospective multicenter study of active surveillance., Materials and Methods: We studied 905 men in the prospective Canary PASS enrolled between 2008 and 2013. We collected clinical data at study entry and at prespecified intervals, and determined associations with adverse reclassification, defined as increased Gleason grade or greater cancer volume on followup biopsy. We also evaluated the relationships of clinical parameters with pathology findings in participants who underwent surgery after a period of active surveillance., Results: At a median followup of 28 months 24% of participants experienced adverse reclassification, of whom 53% underwent treatment while 31% continued on active surveillance. Overall 19% of participants received treatment, 68% with adverse reclassification, while 32% opted for treatment without disease reclassification. In multivariate Cox proportional hazards modeling the percent of biopsy cores with cancer, body mass index and prostate specific antigen density were associated with adverse reclassification (p=0.01, 0.04, 0.04, respectively). Of 103 participants subsequently treated with radical prostatectomy 34% had adverse pathology, defined as primary pattern 4-5 or nonorgan confined disease, including 2 with positive lymph nodes, with no significant relationship between risk category at diagnosis and findings at surgery (p=0.76)., Conclusions: Most men remain on active surveillance at 5 years without adverse reclassification or adverse pathology at surgery. However, clinical factors had only a modest association with disease reclassification, supporting the need for approaches that improve the prediction of this outcome., (Copyright © 2016 American Urological Association Education and Research, Inc. Published by Elsevier Inc. All rights reserved.)

Published
2016
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results